fbpx

News

Lundbeckfonden Ventures News

SAN DIEGO, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
A conference call will be held tomorrow, 21 August, 2014 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York).To access the live conference call, please dial one of the following numbers:+45 32 72 80 18+45 32 72 80 18 (Denmark)44 (0) 1452 555 131 (UK)+1 866 682 84901 866 682...
SAN DIEGO, Aug. 18, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the...
SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $9.50 per share. The gross proceeds to Celladon from this...
SAN DIEGO, Aug. 11, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that the first patient has been dosed in a clinical trial titled “Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with...
SAN DIEGO, Aug. 7, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it is offering to sell 4,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Celladon will also...
SAN DIEGO, Aug. 7, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced financial results for the quarter ended June 30, 2014 and recent highlights. “We have had very positive recent developments with MYDICAR. Last quarter’s FDA Breakthrough...
1 44 45 46 47 48 63

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma to Announce its Results for the Full Year 2019 on 2 March 2020 and Provides Notice of its Annual General Meeting
27. February 2020
Acacia Pharma Group PLC – Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)
27. February 2020
Spero Therapeutics to Present at March Investor Conferences
27. February 2020